Loading…
Underlying
Underlying Price
$6.01
Type
Put
Strike
10
Expiration
Dec 4, 2026
DTE
21d
Moneyness
ITM
Intrinsic
$3.99
IBRX 10 Put Across Expirations
| Expiration | DTE | Last | Change | Vol | Open Int |
|---|---|---|---|---|---|
| Nov 13, 2026 | 0d | $2.02 | -1.94% | 41 | 1 |
| Nov 20, 2026 | 7d | $2.20 | +2.33% | 22 | 680 |
| Nov 27, 2026 | 14d | $2.13 | +40.13% | 4 | 4 |
| Dec 4, 2026 | 21d | $2.06 | +28.75% | 1 | 54 |
| Dec 11, 2026 | 28d | — | — | 0 | 19 |
| Dec 18, 2026 | 35d | $2.56 | +0.00% | 2 | 5 |
| Dec 24, 2026 | 41d | — | — | 0 | 0 |
| Dec 31, 2026 | 48d | — | — | 0 | 0 |
| Jan 15, 2027 | 63d | $2.49 | +8.26% | 5 | 5,915 |
| Mar 19, 2027 | 126d | $2.40 | -4.00% | 10 | 84 |
| Apr 16, 2027 | 154d | $3.23 | -32.71% | 7 | 17 |
| May 21, 2027 | 189d | $3.00 | -36.17% | 10 | 165 |
| Aug 20, 2027 | 280d | $4.70 | +0.00% | 1 | 16 |
| Nov 19, 2027 | 371d | $2.50 | +0.00% | 1 | 1 |
| Jan 21, 2028 | 434d | $3.60 | -3.74% | 15 | 3,779 |
| Mar 17, 2028 | 490d | $4.00 | -6.32% | 1 | 22 |
| Jan 19, 2029 | 798d | $4.92 | +6.96% | 70 | 119 |
IBRX Nearby Strikes · Dec 4, 2026
IBRX Profile
immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.